Pharvaris (NASDAQ:PHVS) Hits New 12-Month High – What’s Next?

by · The Markets Daily

Pharvaris N.V. (NASDAQ:PHVS – Get Free Report)’s stock price reached a new 52-week high during trading on Tuesday . The company traded as high as $42.02 and last traded at $41.30, with a volume of 493228 shares trading hands. The stock had previously closed at $35.25.

Analyst Upgrades and Downgrades

Several research firms have issued reports on PHVS. HC Wainwright reaffirmed a “buy” rating on shares of Pharvaris in a report on Friday, August 14th. Citigroup reiterated a “market outperform” rating on shares of Pharvaris in a report on Thursday, August 13th. HSBC upgraded Pharvaris to an “overweight” rating in a research note on Thursday, August 13th. Citizens Jmp upped their target price on Pharvaris from $74.00 to $75.00 and gave the company a “market outperform” rating in a research report on Thursday, August 13th. Finally, New Street Research set a $60.00 price target on Pharvaris in a research note on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pharvaris presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.08.

Get Our Latest Research Report on PHVS

Pharvaris Price Performance

The stock’s fifty day simple moving average is $34.79 and its 200-day simple moving average is $31.12. The firm has a market cap of $2.64 billion, a PE ratio of -13.21 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS – Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Analysts expect that Pharvaris N.V. will post -3.15 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Berndt Modig sold 2,292 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $34.77, for a total transaction of $79,692.84. Following the completion of the transaction, the chief executive officer directly owned 130,625 shares in the company, valued at $4,541,831.25. The trade was a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the completion of the sale, the director directly owned 315,167 shares in the company, valued at approximately $11,185,276.83. The trade was a 8.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 118,655 shares of company stock worth $4,188,002.

Institutional Investors Weigh In On Pharvaris

Hedge funds have recently bought and sold shares of the stock. venBio Partners LLC acquired a new stake in shares of Pharvaris during the 2nd quarter worth approximately $160,569,809. Deerfield Management Company L.P. lifted its stake in shares of Pharvaris by 21.1% in the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after purchasing an additional 425,000 shares during the period. Wellington Management Group LLP boosted its holdings in Pharvaris by 12.9% during the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock worth $82,748,000 after buying an additional 274,034 shares in the last quarter. Commodore Capital LP boosted its holdings in Pharvaris by 1.6% during the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock worth $54,211,000 after buying an additional 29,525 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP grew its position in Pharvaris by 72.7% during the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock valued at $45,796,000 after buying an additional 772,583 shares during the period.

About Pharvaris

(Get Free Report)

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

Further Reading